FFB Receives $1 Million Gift to Advance Research for XLRP
Thanks to a $1 million gift to the Foundation Fighting Blindness, researchers are one step closer to curing a severe, vision-robbing retinal disease known as X-linked retinitis pigmentosa (XLRP).
The gift, provided by an anonymous donor, will be used to accelerate the advancement of potential XLRP treatments into and through clinical trials. The Foundation has established a consortium of the world’s leading XLRP investigators to identify treatment targets and preclinical disease models for potential therapies. The Foundation Fighting Blindness is currently working to raise a total of $3 million for the first phase of the effort, which will last three years. The second phase of the project will require substantially more revenue to fund clinical trials.
- Synthetic Form of Active Marijuana Ingredient Preserves Vision in Rats with RP
- First Patients Receive Commercial Implant of Argus II Bionic Retina
- RP Gene Therapy Improves Vision After Significant Retinal Degeneration
- GenSight’s Optogenetic Therapy Advancing Toward Human Study
- Tackling the Next Gene Therapy Challenge: Autosomal Dominant Diseases